Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Shed GP of Ebola virus triggers immune activation and increased vascular permeability.

Escudero-Pérez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE.

PLoS Pathog. 2014 Nov 20;10(11):e1004509. doi: 10.1371/journal.ppat.1004509. eCollection 2014 Nov.

2.

Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.

Olejnik J, Forero A, Deflubé LR, Hume AJ, Manhart WA, Nishida A, Marzi A, Katze MG, Ebihara H, Rasmussen AL, Mühlberger E.

J Virol. 2017 May 12;91(11). pii: e00179-17. doi: 10.1128/JVI.00179-17. Print 2017 Jun 1.

3.

Structures of Ebola virus GP and sGP in complex with therapeutic antibodies.

Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE Jr, Andersen KG, Saphire EO, Ward AB.

Nat Microbiol. 2016 Aug 8;1(9):16128. doi: 10.1038/nmicrobiol.2016.128.

4.

Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.

Li W, Ye L, Carrion R Jr, Mohan GS, Nunneley J, Staples H, Ticer A, Patterson JL, Compans RW, Yang C.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S398-403. doi: 10.1093/infdis/jiv186. Epub 2015 Apr 14.

5.

Ebola and Marburg virus-like particles activate human myeloid dendritic cells.

Bosio CM, Moore BD, Warfield KL, Ruthel G, Mohamadzadeh M, Aman MJ, Bavari S.

Virology. 2004 Sep 1;326(2):280-7.

6.

The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide.

Jin H, Yan Z, Prabhakar BS, Feng Z, Ma Y, Verpooten D, Ganesh B, He B.

J Gen Virol. 2010 Feb;91(Pt 2):352-61. doi: 10.1099/vir.0.017343-0. Epub 2009 Oct 14.

7.

Immunopathogenesis of severe acute respiratory disease in Zaire ebolavirus-infected pigs.

Nfon CK, Leung A, Smith G, Embury-Hyatt C, Kobinger G, Weingartl HM.

PLoS One. 2013 Apr 23;8(4):e61904. doi: 10.1371/journal.pone.0061904. Print 2013.

8.

Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways.

Ayithan N, Bradfute SB, Anthony SM, Stuthman KS, Dye JM, Bavari S, Bray M, Ozato K.

J Interferon Cytokine Res. 2014 Feb;34(2):79-89. doi: 10.1089/jir.2013.0035. Epub 2013 Oct 8.

9.

The Myeloid LSECtin Is a DAP12-Coupled Receptor That Is Crucial for Inflammatory Response Induced by Ebola Virus Glycoprotein.

Zhao D, Han X, Zheng X, Wang H, Yang Z, Liu D, Han K, Liu J, Wang X, Yang W, Dong Q, Yang S, Xia X, Tang L, He F.

PLoS Pathog. 2016 Mar 4;12(3):e1005487. doi: 10.1371/journal.ppat.1005487. eCollection 2016 Mar. Erratum in: PLoS Pathog. 2016 Mar;12(3):e1005542.

10.

Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1.

Okumura A, Pitha PM, Yoshimura A, Harty RN.

J Virol. 2010 Jan;84(1):27-33. doi: 10.1128/JVI.01462-09.

11.

RNA Editing of the GP Gene of Ebola Virus is an Important Pathogenicity Factor.

Volchkova VA, Dolnik O, Martinez MJ, Reynard O, Volchkov VE.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S226-33. doi: 10.1093/infdis/jiv309. Epub 2015 Jul 2.

PMID:
26138826
12.

Shedding of Ebola Virus Surface Glycoprotein Is a Mechanism of Self-regulation of Cellular Cytotoxicity and Has a Direct Effect on Virus Infectivity.

Dolnik O, Volchkova VA, Escudero-Perez B, Lawrence P, Klenk HD, Volchkov VE.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S322-8. doi: 10.1093/infdis/jiv268. Epub 2015 Jun 19.

PMID:
26092855
13.

Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.

Favier AL, Gout E, Reynard O, Ferraris O, Kleman JP, Volchkov V, Peyrefitte C, Thielens NM.

J Virol. 2016 May 12;90(11):5256-5269. doi: 10.1128/JVI.00232-16. Print 2016 Jun 1.

14.

Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection.

Zhang X, Ao Z, Bello A, Ran X, Liu S, Wigle J, Kobinger G, Yao X.

Antiviral Res. 2016 Mar;127:20-31. doi: 10.1016/j.antiviral.2016.01.001. Epub 2016 Jan 9.

PMID:
26778707
15.

Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.

Martinez O, Tantral L, Mulherkar N, Chandran K, Basler CF.

J Infect Dis. 2011 Nov;204 Suppl 3:S825-32. doi: 10.1093/infdis/jir295.

16.

Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs.

Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, Saikh KU, Heidebrink KD, Jahrling PB, Ulrich RG, Schmaljohn CS.

Virus Res. 2003 Apr;92(2):187-93.

PMID:
12686428
17.

Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.

Mohan GS, Li W, Ye L, Compans RW, Yang C.

PLoS Pathog. 2012;8(12):e1003065. doi: 10.1371/journal.ppat.1003065. Epub 2012 Dec 13.

18.

Clinical features and pathobiology of Ebolavirus infection.

Ansari AA.

J Autoimmun. 2014 Dec;55:1-9. doi: 10.1016/j.jaut.2014.09.001. Epub 2014 Sep 26. Review.

PMID:
25260583
19.

The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses.

Lubaki NM, Younan P, Santos RI, Meyer M, Iampietro M, Koup RA, Bukreyev A.

PLoS Pathog. 2016 Dec 8;12(12):e1006031. doi: 10.1371/journal.ppat.1006031. eCollection 2016 Dec.

20.

Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection.

Okumura A, Rasmussen AL, Halfmann P, Feldmann F, Yoshimura A, Feldmann H, Kawaoka Y, Harty RN, Katze MG.

J Virol. 2015 Oct;89(20):10399-406. doi: 10.1128/JVI.01736-15. Epub 2015 Aug 5.

Supplemental Content

Support Center